Redx Pharma subsidiary will take over part of AstraZeneca site in U.K.
AstraZeneca, a global research-based biopharmaceutical company, announced in March that it would move some of its research and more than 1,000 jobs away from Alderley Park to Cambridge. Redx Anti-Infectives will join Imagen Biotech, Blueberry Therapeutics and BioCity Nottingham as new tenants of the site, which is being called a BioHub, PharmaTimes.com reports.
Redx Anti-Infectives, which began operations at the end of April with the support of a $7.2 million government grant, will focus on difficult-to-treat infections like Methicillin-resistant Staphylococcus aureus, HIV, hepatitis C and influenza.
"The World Health Organization has identified drug resistance, particularly in the area of antibiotics, as one of the most pressing human health concerns globally," Neil Murray, the chief executive of Redx Pharma, said, according to PharmaTimes.com. "The fresh thinking and original approach of Redx Anti-Infectives will help create effective solutions to these critical problems. Whilst our headquarters remain in Liverpool and we have ambitious plans to grow our business and create high value science posts in the city, at the same time we recognize that the facilities at Alderley Park are world class and enable us to move quickly in expanding this key new part of our business."
Murray said Redx Anti-Infectives will work closely with its colleagues at AstraZeneca and that the company looks forward to a long and fruitful collaboration. Chris Morris, AstraZeneca's vice president of R&D echoed Murray's sentiments, PharmaTimes.com reports.
"We are delighted to welcome Redx to Alderley Park, which is an important first step in our ambition to secure a sustainable future for the site," Morris said, according to PharmaTimes.com. "We will continue to seek further opportunities to attract other innovation-driven companies and, wherever possible, build on the existing bioscience expertise and world class facilities available at Alderley Park."